NCT06781281View on ClinicalTrials.gov

NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.

RecruitingOBSERVATIONAL

Enrollment

709

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

November 28, 2026

Study Completion Date

November 28, 2030

Conditions

Breast Cancer Invasive

Interventions

DRUG

Serplulimab

Serplulimab

DRUG

NabPE

Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2

Trial Locations (1)

Unknown

RECRUITING

Henan cancer hospital, Zhengzhou

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV